ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD20 Monoclonal Antibody MIL62

Also written as “MIL62”, “Recombinant Humanized Monoclonal Antibody MIL62 Injection” and “Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide”.

Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, Membranous · Lymphoma, Follicular · Neuromyelitis Optica · Lupus Nephritis, led by 2 companies.

Drug pageAnti-CD20 Monoclonal Antibody MIL62: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 5, 202110 company-led studies, 7 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Mabworks Biotechits history only96 open or runningphase 3since Apr 5, 2021Sep 18, 2019Dec 2028phase 3 · NCT07405970
InnoCare Pharmaits history only11 open or runningphase 2since Mar 5, 2020Mar 5, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2019First study: phase 1 study in CD20-positive B Cell Non-Hodgkin LymphomaNew to Beijing Mabworks BiotechBeijing Mabworks Biotech · NCT04103905 · 27 enrolled · China
  2. Sep 27, 2019Phase 2 study in Lymphoma, FollicularBeijing Mabworks Biotech · NCT04110301 · 53 planned · China
  3. Mar 5, 2020InnoCare Pharma’s first study: phase 2 study in B-cell Lymphoma RecurrentNew to InnoCare PharmaInnoCare Pharma · NCT04304040 · 43 enrolled · China
  4. Apr 5, 2021Phase 3 study in Lymphoma, FollicularBeijing Mabworks Biotech · NCT04834024 · 168 planned · China
  5. Mar 29, 2022Phase 3 study in Neuromyelitis OpticaBeijing Mabworks Biotech · NCT05314010 · 102 enrolled · China
  6. May 26, 2022Phase 2 study in Primary Membranous NephropathyBeijing Mabworks Biotech · NCT05398653 · 94 enrolled · China
  7. Mar 8, 2023Phase 2 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT05796206 · 123 enrolled · China
  8. May 8, 2023Phase 3 study in Primary Membranous NephropathyBeijing Mabworks Biotech · NCT05862233 · 150 enrolled · China
  9. Jun 23, 2025Phase 2 study in Lupus NephritisBeijing Mabworks Biotech · NCT07044115 · 41 enrolled · China
  10. Feb 5, 2026Phase 3 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT07405970 · 316 planned · China

Ahead

  1. Dec 2028Primary completion: phase 3 study in Lupus Erythematosus, SystemicBeijing Mabworks Biotech · NCT07405970

TargetBeta

MS4A1 →read by rule
“A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, ”NCIt, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07405970Lupus Erythematosus, Systemic · China3RecruitingBeijing Mabworks BiotechDec 2028316
NCT07044115Lupus Nephritis · China2Active, not recruitingBeijing Mabworks BiotechJan 16, 202541
NCT05862233Primary Membranous Nephropathy · China3Active, not recruitingBeijing Mabworks BiotechMay 13, 2025150
NCT05796206Lupus Erythematosus, Systemic · China2CompletedBeijing Mabworks BiotechNov 21, 2024123
NCT05398653Primary Membranous Nephropathy · China2CompletedBeijing Mabworks BiotechMar 4, 202594
NCT05314010Neuromyelitis Optica · China3Active, not recruitingBeijing Mabworks BiotechFeb 21, 2025102
NCT04834024Lymphoma, Follicular · China3RecruitingBeijing Mabworks BiotechMar 2025168
NCT04304040B-cell Lymphoma Recurrent · China2Active, not recruitingInnoCare PharmaDec 30, 202543
NCT04110301Lymphoma, Follicular · China2RecruitingBeijing Mabworks BiotechJan 9, 202453
NCT04103905CD20-positive B Cell Non-Hodgkin Lymphoma · China1CompletedBeijing Mabworks BiotechMay 30, 201927

How it is read

Names in the registry

  • “MIL62”, 6 entries
  • “Recombinant Humanized Monoclonal Antibody MIL62 Injection”, 3 entries
  • “Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide”, 1 entry
  • “Recombinant humanized monoclonal antibody MIL62 injection”, 1 entry

Codes read as this program: MIL62.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.